Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil)

被引：0
|
作者：
N. Hatam
N. Ahmadloo
A. Ahmad Kia Daliri
P. Bastani
M. Askarian
机构：
[1] Shiraz University of Medical Science,School of Management and Medical Information Sciences
[2] Shiraz University of Medical Science,Department of Radiation Oncology, Namazi Hospital
[3] Lund University,Division of the Health Economics, Center for Primary Health Care Research
[4] Shiraz University of Medical Science (SUMS),Community Medicine Department
[5] Shiraz University of Medical Science (SUMS),undefined
来源：
Archives of Gynecology and Obstetrics | 2011年 / 284卷
关键词：
Quality of life; Toxicity; Adjuvant therapy; Breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：215 / 220
页数：5
相关论文
共 50 条
  • [1] Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil)
    Hatam, N.
    Ahmadloo, N.
    Kiadaliri, A. Ahmad
    Bastani, P.
    Askarian, M.
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2011, 284 (01) : 215 - 220
  • [2] Comparison of Docetaxel, Doxorubicin and Cyclophosphamide (TAC) with 5-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: A Phase III Clinical Trial
    Omidvari, Shapour
    Hosseini, Sare
    Ashouri, Yaghoub
    Tahmasebi, Sedigheh
    Talei, Abdolrasoul
    Nasrolahi, Hamid
    Ahmadloo, Niloofar
    Ansari, Mansour
    Mosalaei, Ahmad
    Mohammadianpanah, Mohammad
    [J]. MIDDLE EAST JOURNAL OF CANCER, 2011, 2 (02) : 51 - 58
  • [3] Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC):: impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen
    Martin, M.
    Lluch, A.
    Segui, M. A.
    Ruiz, A.
    Ramos, M.
    Adrover, E.
    Roriguez-Lescure, A.
    Grosse, R.
    Calvo, L.
    Fernandez-Chacon, C.
    Roset, M.
    Anton, A.
    Isla, D.
    Martinez del Prado, P.
    Iglesias, L.
    Zaluski, J.
    Arcusa, A.
    Loez-Vega, J. M.
    Munoz, M.
    Mel, J. R.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (08) : 1205 - 1212
  • [4] A cost effectiveness analysis of adjuvant chemotherapy for node positive early breast cancer in South Africa: docetaxel, doxorubicin and cyclophosphamide (TAC) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)
    Rapoport, B. L.
    Moodley, S. D.
    Jacobs, C.
    Pienaar, R.
    Fourie, S.
    Szpak, W. M.
    [J]. BREAST, 2007, 16 : S64 - S64
  • [5] Impact of adjuvant chemotherapy with docetaxel for early breast cancer:: Cost-effectiveness analysis (CEA) of a docetaxel, doxorubicin and cyclophosphamide regimen (TAC) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in France
    Miadi-Fargier, H
    Le Pen, C
    Woronoff-Lemsi, MC
    Guastalla, JP
    Pivot, X
    Roché, H
    Pinguet, F
    Favier, B
    Gligorov, J
    Debrix, I
    Spielmann, M
    Antoine, EC
    Cadilhac, M
    De Pouvourville, GA
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A36 - A37
  • [6] Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)
    Sang Gyu Lee
    Young Geon Jee
    Hyun Chul Chung
    Sung-Bae Kim
    Jungsil Ro
    Young-Hyuck Im
    Seock-Ah Im
    Jae Hong Seo
    [J]. Breast Cancer Research and Treatment, 2009, 114 : 589 - 595
  • [7] Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)
    Lee, Sang Gyu
    Jee, Young Geon
    Chung, Hyun Chul
    Kim, Sung-Bae
    Ro, Jungsil
    Im, Young-Hyuck
    Im, Seock-Ah
    Seo, Jae Hong
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 589 - 595
  • [8] Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin and cyclophosphamide regimen (TAC) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in early breast cancer at the Mexican Social Security Institute (IMSS) Mexico
    Valle-Solis, Aura A. Erazo
    Olivares, Guillermo
    Lazaro, Miguel
    Maurel, Frederique
    Robles, Jesus
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 107 - 107
  • [9] Doxorubicin and Cyclophosphamide versus Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Adjuvant Chemotherapy in Breast Cancer
    Livi, L.
    Saieva, C.
    Borghesi, S.
    Cardillo, C. De Luca
    Scotti, V.
    Mangoni, M.
    Greto, D.
    Cataliotti, L.
    Paiar, F.
    Bianchi, S.
    Biti, G. P.
    [J]. JOURNAL OF CHEMOTHERAPY, 2009, 21 (05) : 558 - 565
  • [10] Toxicity and health-related quality of life (HRQoL) in node-negative breast cancer (BC) patients (pts) receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC (5-fluorouracil, doxorubicin, cyclophosphamide):: Impact of adding prophylactic growth factors (GF) to TAC.: GEICAM Study 9805.
    Martin, M
    Lluch, A
    Seguí, MA
    Antón, A
    Fernández-Chacón, C
    Ruíz, A
    Ramos, M
    Adrover, E
    Rodríguez-Lescure, A
    Casado, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 29S - 29S
12345